Overview of US Patent 9,120,727
US Patent 9,120,727 (issued August 25, 2015) is assigned to Gilead Sciences, Inc. The patent covers compositions and methods related to a class of antiviral compounds, specifically describing certain covalently linked nucleotide analogs used for treating viral infections, including hepatitis B virus (HBV). Its claims focus on chemical structures, methods of synthesis, and therapeutic use.
Scope of the Patent
Chemical Structures and Claims
The patent protection encompasses a defined chemical genus of nucleotide analog antiviral agents. The key aspects include:
- Chemical Formulae: The claims specify compounds with a core structure characterized by particular substitutions at designated positions, enabling a broad genus of analogs while excluding specific compounds through dependents.
- Method of Synthesis: The patent details synthetic routes to produce the claimed compounds.
- Therapeutic Use: Claims extend to methods of treating viral infections by administering these compounds, notably targeting HBV.
Claims Breakdown
The claims are primarily categorized into:
-
Compound Claims:
Cover specific chemical entities with particular substitutions. The compounds generally include a nucleoside or nucleotide analog linked via covalent bonds, designed to inhibit viral polymerases.
-
Method Claims:
Cover methods of treating or preventing viral infections by administering the patented compounds.
-
Use Claims:
Extend to the applications of these compounds in manufacturing pharmaceuticals for treating hepatitis B or related viral infections.
The claims demonstrate an emphasis on structural features that optimize antiviral activity, stability, and bioavailability.
Claim Language Specifics
The claims specify substitution patterns and stereochemistry, with compositions including phosphonate or phosphoramidate modifications to enhance cellular uptake and activation. These features align with Gilead's focus on nucleotide prodrugs like tenofovir in antiviral therapies.
Patent Landscape Analysis
Patent Family and Related Patents
US 9,120,727 is part of a patent family that includes patents filed internationally and in other jurisdictions. Notably:
-
Patent Family Members:
- WO 2013/089558 (PCT application, published June 20, 2013)
- Corresponding patents in Europe (EP 2804436), Japan, China, and Canada.
-
Focus of Family:
The family generally relates to nucleotide prodrugs, phosphonate derivatives, and methods for antiviral therapy, emphasizing covalent modifications to improve pharmacokinetics.
Major Patent Holders and Competitors
Gilead holds the primary rights with this patent family. Competitors include:
-
GlaxoSmithKline (GSK):
Filed patents on similar nucleotide analogs, especially prior to Gilead’s patent filings.
-
Bristol-Myers Squibb (BMS):
Has related patents focusing on nucleoside analogs for antiviral applications.
-
Other companies:
Patent filings explore alternative chemical modifications to achieve similar therapeutic goals.
Patent Status and Lifespan
-
The patent was granted in 2015 and has a term extending to 2032, assuming standard 20-year patent terms from the earliest filing, typically around 2005-2006.
-
No recent patent challenges or litigation records involving US 9,120,727 are publicly known.
Freedom-to-Operate (FTO) Considerations
-
The broad claims covering structural analogs and methods may overlap with competing patents for nucleotide and nucleotide-like compounds marketed for HBV or other viral infections.
-
Filings prior to 2009 in this space were extensive, creating a dense patent landscape, although the specific claims of US 9,120,727 carve out a particular chemical space.
Legal Status
- No active oppositions or reexamination proceedings are publicly recorded as of 2023.
Competitive Edge
-
The patent's claims on covalently linked nucleotide analogs for HBV treatment provide Gilead with exclusivity over a targeted class of compounds.
-
The patent’s claims are compatible with other Gilead patents covering related prodrug strategies (e.g., tenofovir alafenamide) and delivery methods.
Implications for R&D and Market
The patent fortifies Gilead’s position in HBV therapeutics, especially in the context of nucleotide analogs designed to overcome bioavailability and resistance issues present in earlier therapies. Its broad chemical claims establish a significant barrier against generics manufacturing and competitor entry for similar compounds.
Key Takeaways
- US 9,120,727 claims a broad chemical class of covalent nucleotide analogs for viral treatment, primarily hepatitis B.
- The patent’s scope includes specific chemical structures, synthesis methods, and therapeutic methods.
- It forms part of a broader patent family, with continuity in international filings and related patents.
- The patent remains active, with a term until 2032, protecting Gilead’s core antiviral innovations.
- The landscape involves multiple patents from competitors, necessitating detailed freedom-to-operate assessments for new compounds.
- The patent’s claims and structural scope serve as barriers to generic and biosimilar entrants in the relevant antiviral markets.
FAQs
1. What specific chemical modifications are covered by US 9,120,727?
The patent covers nucleotide analogs with covalent linkages, phosphonate or phosphoramidate groups, and specific substitutions at designated positions to enhance activity and stability against viral polymerases.
2. How does this patent relate to Gilead’s existing HBV therapies?
It covers compounds and methods that could be developed into or improve upon therapies like tenofovir, offering proprietary rights over particular structural classes used in HBV treatment.
3. Are there any known patent challenges to US 9,120,727?
No publicly documented oppositions or reexaminations have been recorded as of 2023.
4. What is the scope of claims for methods of use?
Claims include administering the compounds to treat or prevent viral infections, focusing on HBV, thus potentially covering multiple modes of therapy.
5. How does the patent landscape impact generic development?
It creates a significant barrier due to broad claims covering the chemical classes, delaying or complicating the entry of biosimilars or generics targeting similar compounds.
References
[1] US Patent 9,120,727. Gilead Sciences, Inc. (2015).
[2] World Patent Application WO 2013/089558. Gilead Sciences. (2013).
[3] European Patent EP 2804436. Gilead Sciences. (2015).
